CDK9-IN-37

• Description :

  CDK9-IN-37 (Compound 24) is a CDK9 inhibitor (EC50: 5.5 nM) with weak inhibition on other CDK isoforms, showing high selectivity. CDK9-IN-37 has significant antiproliferative activity against acute myeloid leukemia MOLM-13 cells (IC50: 0.034 μM) . CDK9-IN-37 inhibits the CDK9 signaling pathway, reduces the phosphorylation level of RNAP II CTD (Ser2), downregulates the anti-apoptotic protein McI-1, induces cell apoptosis, and arrests the cell cycle at the G2/M phase. CDK9-IN-37 can be used in the study of acute myeloid leukemia (AML) [1].

• UNSPSC :

  12352005

• Target :

  CDK

• Related Pathways :

  Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  CCOC1=C(C(C2=CN=C(NC3=CC(C)=CC(S(=O)(C)=O)=C3)S2)=O)C=CC(F)=C1

• Molecular Formula :

  C20H19FN2O4S2

• Molecular Weight :

  434.50

• References & Citations :

  [1]Chen S, et al. Design, synthesis and bio-evaluation of 2,5-disubstituted thiazole derivatives for potential treatment of acute myeloid leukemia through targeting CDK9. Bioorg Chem. 2025 Jun 15;160:108436.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK9